Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2007-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4088/JCP.V68N0602PMID 17592905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation

  2007cited by this paper
• A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression

  2006cited by this paper
• Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

  2005cited by this paper
• Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

  2005cited by this paper
• Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients.

  2005cited by this paper
• Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.

  2005cited by this paper
• Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance

  2005cited by this paper
• Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.

  2005cited by this paper
• Aripiprazole as an adjunctive treatment for refractory major depression.

  2004cited by this paper
• Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence.

  2004cited by this paper
• The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.

  2004cited by this paper
• Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine

  2004cited by this paper
• Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors

  2004cited by this paper
• Side effects of atypical antipsychotic drugs.

  2004cited by this paper
• Augmentation of milnacipran by risperidone in treatment for major depression.

  2004cited by this paper
• Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.

  2004cited by this paper
• Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation.

  2003cited by this paper
• Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.

  2003cited by this paper
• Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.

  2003cited by this paper
• A novel augmentation strategy for treating resistant major depression.

  2001cited by this paper
• Addition of olanzapine for treatment-resistant depression.

  2001cited by this paper
• Tranylcypromine plus risperidone for treatment-refractory major depression.

  2000cited by this paper
• Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

  1999cited by this paper
• Understanding research synthesis (meta-analysis).

  1996cited by this paper
• Residual symptoms after partial remission: an important outcome in depression

  1995cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Leveraging topological indices and machine learning for advanced prediction of antidepressant drug properties

  2026cites this paper
• Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder.

  2025cites this paper
• A molecular mechanism mediating clozapine-enhanced sensorimotor gating

  2025cites this paper
• Explainable Counterfactual Reasoning in Depression Medication Selection at Multi-Levels (Personalized and Population)

  2025cites this paper
• LSD: Mechanisms and Relevance to the Treatment of Depression.

  2025cites this paper
• Healthcare resource utilization with adjunctive cariprazine and other atypical antipsychotics in patients with major depressive disorder

  2025cites this paper
• A systematic review of augmentation strategies for patients with major depressive disorder.

  2025cites this paper
• Real-World Disability Outcomes Among Patients Treated with Cariprazine vs Other Atypical Antipsychotics as Adjunctive Treatment for Major Depressive Disorder

  2025cites this paper
• Role of adjunctive cariprazine for treatment-resistant depression in patients with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• Adjunctive cariprazine for the treatment of major depressive disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

  2024cites this paper
• Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2).

  2024cites this paper
• Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial

  2024cites this paper
• Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials

  2024cites this paper
• A Bibliometric Analysis of the WoSCC Literature on the Use of Selective Serotonin Reuptake Inhibitors as Antidepressants

  2024cites this paper
• How should we design future mechanistic and/or efficacy clinical trials?

  2023cites this paper
• Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

  2023cites this paper
• Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study.

  2023cites this paper
• Latin American consensus recommendations for the management and treatment of patients with treatment-resistant depression (TRD).

  2023cites this paper
• Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder

  2023cites this paper
• Associations between mortality and exposure to psychotropic medication: A population-based cohort study for depressive disorders

  2023cites this paper
• Annual costs among patients with major depressive disorder and the impact of key clinical events

  2022cites this paper
• Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database Analysis

  2022cites this paper
• Interactions of Apigenin and Safranal with the 5HT1A and 5HT2A Receptors and Behavioral Effects in Depression and Anxiety: A Molecular Docking, Lipid-Mediated Molecular Dynamics, and In Vivo Analysis

  2022cites this paper
• Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis

  2022cites this paper
• Efficacy and Safety of Adjunctive Serotonin‐Dopamine Activity Modulators in Major Depression: A Meta‐Analysis of Randomized Controlled Trials

  2021cites this paper
• Treatment resistant depression

  2021cites this paper
• Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week, Two-Site, Randomized, Placebo-Controlled Study

  2020cites this paper
• The identification, assessment and management of difficult-to-treat depression: An international consensus statement.

  2020cites this paper
• Importance of Distinguishing Reactive and Proactive Aggression in Dementia Care

  2020cites this paper
• Comorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment.

  2020cites this paper
• Pharmacological Treatment of Major Depressive Disorder

  2020cites this paper
• Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression.

  2020cites this paper
• Simultaneous Quantification of 38 Psychotropic Drugs and Relevant Metabolites in Blood using LC-MS-MS.

  2020cites this paper
• Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.

  2020cites this paper
• Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines

  2020cites this paper
• The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF).

  2019cites this paper
• CEOR_A_220007 741..755

  2019cites this paper
• Effects of combined escitalopram and aripiprazole in rats: role of the 5-HT1a receptor

  2019cites this paper
• Optimized Treatment Strategy for Depressive Disorder.

  2019cites this paper
• Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea

  2019cites this paper
• Depressive Disorders: Mechanisms, Measurement and Management

  2019cites this paper
• The Massachusetts General Hospital Guide to Depression

  2019cites this paper
• Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder

  2019cites this paper
• Tachyphylaxis in major depressive disorder: A review of the current state of research.

  2019cites this paper
• Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study

  2019cites this paper
• Major Depressive Disorder (MDD) and Schizophrenia– Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review

  2019cites this paper
• Adult Hippocampal Neurogenesis: Regulation and Possible Functional and Clinical Correlates

  2018cites this paper
• The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex

  2018cites this paper
• Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder

  2018cites this paper
• Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus

  2018cites this paper
• Depression

  2018cites this paper
• Behavioral Problems and Dementia.

  2018cites this paper
• Assessment of health-related quality of life , patient-reported mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression

  2018cites this paper
• Treatment-Resistant Depression

  2018cites this paper
• COMBINATION OF ANTIDEPRESSANTS

  2018cites this paper
• Change in 1-year hospitalization of overall and older patients with major depressive disorder after second-generation antipsychotics augmentation treatment.

  2018cites this paper
• Life Care Planning and Case Management Handbook

  2018cites this paper
• Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis

  2017cites this paper
• Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results

  2017cites this paper
• Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial

  2017cites this paper
• Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression

  2017cites this paper
• The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression

  2017cites this paper
• Importance of context in management of behavioral symptoms of dementia

  2017cites this paper
• Characterization of the adrenocorticotrophic hormone ‐ induced mouse model of resistance to antidepressant drug treatment

  2017influential citation
• Antipsychotic augmentation for major depressive disorder: A review of clinical practice guidelines.

  2017cites this paper
• Praxis der Kombinations- und Augmentationsbehandlung bei Nichtansprechen auf antidepressive Monotherapie

  2017cites this paper
• Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine

  2017cites this paper
• Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling

  2016cites this paper
• A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression

  2016cites this paper
• Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes.

  2016cites this paper
• Noninvasive brain stimulation treatments for addiction and major depression

  2016cites this paper
• Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation

  2016cites this paper
• Clinical correlates of difficult-to-treat depression: Exploring an integrated day-care model of treatment

  2016cites this paper
• Recurrent Major Depressive Disorder of a Young Woman.

  2016cites this paper
• Ineffectiveness of nicotinic acetylcholine receptor antagonists for treatment-resistant depression: a meta-analysis

  2016cites this paper
• Molecular biomarkers of depression.

  2016cites this paper
• Ziprasidone augmentation for anxious depression

  2016cites this paper
• Augmentation of effect of venlafaxine by folic acid in behavioral paradigms of depression in mice: Evidence of serotonergic and pro-inflammatory cytokine pathways

  2016cites this paper
• Behandlung depressiver Störungen

  2016cites this paper
• Ziprasidone as Augmentation Agent for Major Depressive Disorder

  2016cites this paper
• Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

  2016influential citation
• DRAFT Health Care Guideline Depression in Primary Care

  2016cites this paper
• Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data

  2016cites this paper
• Antipsychotic Medications in Major Depression and the Association with Treatment Satisfaction and Quality of Life: Findings of Three National Surveys on Use of Psychotropics in China Between 2002 and 2012

  2015cites this paper
• Pharmacological approaches to the challenge of treatment-resistant depression

  2015cites this paper
• Factors Related to Rejection of Care and Behaviors Directed towards Others: A Longitudinal Study in Nursing Home Residents with Dementia

  2015cites this paper
• Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study

  2015cites this paper
• A Review of Psychostimulants for Adults With Depression.

  2015cites this paper
• Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature

  2015cites this paper
• A 13-Week, Randomized Double-Blind, Placebo-Controlled, Cross-Over Trial of Ziprasidone in Bipolar Spectrum Disorder

  2015cites this paper
• Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population.

  2015cites this paper
• Modalités d’utilisation des antidépresseurs

  2015cites this paper
• Characteristics of antidepressant medication users in a cohort of mid-age and older Australians

  2015cites this paper
• Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder

  2015cites this paper
• Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

  2015cites this paper
• Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.

  2015cites this paper
• Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India

  2015influential citation
• Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: A subgroup analysis and Montgomery–Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study

  2015cites this paper
• Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials

  2015cites this paper
• Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis

  2015cites this paper